Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates.
Eloxx has raised $66.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2026.
Eloxx's investors include Hercules Capital, Pontifax, Korea Investment Partners, OPKO Health, Catalyst Fund LP.
Eloxx is headquartered in Waltham, United States.
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates.
Eloxx is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Eloxx — Funding & Investors." VCBacked, June 8, 2026, https://www.vcbacked.co/company/eloxx. Accessed September 30, 2026.
VCBacked. (2026). Eloxx — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/eloxx
{{cite web |title=Eloxx — Funding & Investors |url=https://www.vcbacked.co/company/eloxx |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated